The new, ,90,000-square-foot facility is expected to handle the company’s growth, as Insulet prepares to roll out its new, smaller OmniPod insulin management system, according to a press release.
“We are pleased to announce our relocation to a larger space in Billerica, which is a testament to the success and growth Insulet has experienced since its founding in 2000. With high demand for the new OmniPod and continued development of new management tools for people with both Type I and Type II diabetes, we are excited to find a location that fits our growing needs,” president & CEO Duane DeSisto said in prepared remarks.
Insulet partnered with Amgen (NSDQ:AMGN) in a 5-year deal in support of biotechnology medicine delivery. Insulet will provide Amgen with a delivery device designed for biotechnology medicines, based on the OmniPod.